Across TCGA pan-cancer cohorts, TLCD2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TLCD2 data layer compared with 27 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher TLCD2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TLCD2 expression acts as an unfavorable survival marker.

ESCA are the cancer types where TLCD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: TLCD2 tumor-vs-normal RNA expression · all TLCD2 data types